导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 7.72% | 979/4773 |
| 近一周 | -1.60% | 2359/5465 |
| 近一月 | -1.79% | 1303/5421 |
| 近一季 | -2.25% | 1337/5231 |
| 近半年 | 2.24% | 1075/4920 |
| 近一年 | 12.77% | 926/4394 |
| 近两年 | 77.29% | 886/2954 |
| 近三年 | 53.37% | 515/2253 |
| 成立以来 | 64.82% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.54% 1513/4961 |
11.99% 2256/5312 |
- - |
- - |
| 2025 | 34.98% 1011/4813 |
1.62% 1581/3635 |
3.49% 1003/4076 |
25.70% 1381/4524 |
2.11% 1083/4813 |
| 2024 | 13.65% 1117/3463 |
3.80% 511/2808 |
-3.45% 1374/3014 |
17.33% 1212/3129 |
-3.34% 2328/3463 |
| 2023 | -11.95% 1437/2656 |
2.67% 1319/2280 |
-3.91% 966/2385 |
-3.67% 967/2515 |
-7.35% 2123/2655 |
| 2022 | -20.00% 924/2207 |
-13.42% 755/1919 |
7.97% 407/2016 |
-12.91% 805/2113 |
-1.75% 1734/2208 |
| 2021 | -1.51% 805/1822 |
-2.17% 592/1255 |
5.16% 821/1330 |
-6.17% 903/1466 |
2.03% 720/1822 |
| 2020 | 34.49% 436/1250 |
-7.96% 582/1028 |
15.51% 493/1067 |
12.67% 371/1164 |
12.28% 482/1184 |
| 2019 | - - |
- - |
- - |
- - |
8.13% 349/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 东方红中证竞争力指数A VS. 长安沪深300非周期A(740101) |